Bayer Healthcare LLC

Bayer Technology Services Gmbh

Bayer Intellectual Property Gmbh

Deqian Wang

Clark Qun Pan

Thomas Barnett

John E Murphy

Jonathan S Strauss

Baisong Mei

Jianmin Chen

Liang Tang

Hendri Tjandra

Paul Wu

Arnaud Desponds

Nelly Tsvetkova

Omkar Joshi

Dietrich Gehrmann

Ariane Firus

Thomas Daun

Heinz Müller

Heinz Mueller

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

Factor VIII conjugates

The invention relates to a method for stabilizing a bulk solution of recombinant protein for frozen storage, which comprises providing a partially-purified solution of recombinant protein which has a monovalent salt concentration of at least 100 mM, and adding a carbohydrate to said solution in an amount sufficient that, upon freezing, the solution has a glass transition temperature of &#x2212;56&#xb0; C. or higher.

Stabilization of liquid solutions of recombinant protein for frozen storage

Process for producing containers of a freeze-dried product wherein droplets of the product are frozen to form pellets, the pellets are freeze-dried, assayed and loaded into the containers.

Sterile freezing, drying, storing, assaying and filling process

This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.

Site-directed modification of FVIII

Growing community of inventors

Concord, CA, United States of America

Deqian Wang